Answers are grounded in this paper and cite their sources.
Lay Summary Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
No takes yet. Share an insight, caveat, or question.
Schell et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: